Category: 3. Business

  • Can AI Draft Discharge Summaries as Well as Hospitalists?

    Can AI Draft Discharge Summaries as Well as Hospitalists?

    If she’s especially efficient, Hospitalist Gigi Liu, MD, can complete a discharge summary in 20 minutes for a patient she treated for a few days at The Johns Hopkins Hospital, Baltimore. But summarizing visits with patients who stay longer at the Baltimore hospital “can suck up a whole hour,” she said. The summaries help guide patients’ care once they leave the hospital.

    “Thirty minutes to an hour [of paperwork] is enough time for me to see another patient,” Liu said.

    Liu is hopeful hospitalists will eventually be able to focus more on patient care and less on preparing hospital discharge summaries, among the benefits cited in a new study that used large language models (LLMs) — a form of artificial intelligence (AI) — to draft the narratives. The study by researchers at the University of California San Francisco (UCSF), mostly hospitalists, was published recently in JAMA Internal Medicine.

    Gigi Liu, MD

    It compared hospital discharge summaries created by hospitalists with those drafted by LLMs, which are capable of synthesizing large quantities of information into original content similar to what a doctor might create. The study didn’t find a significant difference in the summaries compiled by doctors and the LLM-generated narratives.

    The latter were more concise and coherent than the physician-generated counterparts, but less comprehensive, the study reported. The LLM summaries also were more likely to contain errors, including omissions and inaccuracies, but still had a low potential for patient harm, the study found.

    The study involved 100 randomly selected inpatient hospital medicine patient encounters of 3-6 days between 2019 and 2022 at UCSF. As part of the blinded study, 22 attending physician reviewers separately evaluated narratives created by hospitalists and those developed by LLM, without knowing which method was used to generate the summaries.

    The reviewers didn’t find much difference between the two methods for overall quality and preference, according to the researchers who analyzed the results.

    As hospitalists who hand off care to each other after stints of time on service, “we join the patient’s journey abruptly” for a week or longer, said Charumathi Raghu Subramanian, MD, one of the lead authors of the new study.

    One duty of the last hospitalist caring for a patient is to discharge them from the hospital, she said.

    “The discharge summary is such an important aspect of the patient’s journey.” It summarizes clinically important aspects of a patient’s care as they transition from the hospital to post-acute community medicine.

    photo of Charumathi Raghu Subramanian
    Charumathi Raghu Subramanian, MD

    The summary serves as a window to all that happened in the hospital for the clinicians who care for the patient after they leave, mostly primary care and skilled nursing facility physicians, Raghu Subramanian told Medscape Medical News. She and another hospitalist specializing in clinical informatics and digital transformation joined 20 other UCSF faculty as study authors.

    Hospitalists sift through all the notes taken by any clinician that interacted with the patient during their hospital stay, she said. “It takes a lot of time.”

    High-quality discharge summaries reduce medication errors, lower hospital readmission rates, and enhance primary care physician satisfaction, according to research the study cited.

    The discharge summaries contain such elements as principal diagnosis, a medication list, and test results. The narrative sections include the patient’s history of illness and hospital course.

    “Unlike a hospital progress note, which often reflects incremental daily documentation effort, a discharge summary can be considerably more involved, particularly for lengthy hospital encounters or when care has been provided by sequential physicians,” the study said.

    In a 2021 survey of 815 American physicians quoted in the UCSF study, 44% of hospitalists said they were too busy to prepare high-quality discharge summaries.

    LLMs, such as generative pretrained transformer, hold promise in healthcare to save clinicians’ time, reduce burnout and increase job satisfaction, the study indicated.

    Raghu Subramanian explained that an LLM can take all the encounter notes extracted from a clinical data warehouse or a clinician can feed the summary of the encounter notes to the LLM to create a new discharge narrative in far less time than it would take a physician.

    Potential for Harm

    While other studies have tested LLMs to create discharge summaries, the UCSF study involved actual hospital encounters with many patients over several days rather than curated vignettes, according to the hospitalist authors Medscape Medical News consulted.

    Study authors thought reviewers should include producers of the discharge summaries, hospitalists, and consumers: skilled nursing and primary care doctors, Raghu Subramanian said.

    The reviewers evaluated the summaries generated by hospitalists and the LLM and scored them separately based on their potential for harm; coherence, conciseness, and comprehensiveness; and which set of summaries reviewers preferred.

    The LLM-generated narratives had more omissions and inaccuracies than the doctors’ summaries. But they contained a similar number of hallucinations — seemingly plausible but fabricated statements — which study authors found noteworthy considering the “well-documented propensity for LLMs to hallucinate.”

    Harm scores based on those errors could range on the low side from no potential for harm to potential for emotional distress or inconvenience, such as mild anxiety, and on the high side to potential for injury or death, the study reported.

    Still, most of the harm scores were low, according to Hospitalist Benjamin Rosner, MD, PhD, senior author the study. “In an ideal world, we want none of those to happen,” Rosner said.

    photo of  Benjamin Rosner
    Benjamin Rosner, MD, PhD

    “When we think of the potential of LLM a lot of people think it has to be perfect. Maybe that’s the wrong benchmark,” he said. He pointed out that the physician-generated discharge summaries also had errors and the potential for harm.

    Many clinicians care for a patient in the hospital, but it is the last physician before discharge, typically a hospitalist, who writes the summary, Rosner explained.

    They have to read through every “inherently messy” hospital encounter note written by many members of the care team from every day of hospitalization, he said.

    From her outside perspective, Liu noted that most of the errors the study found were clerical, such as missing information a hospitalist might want to relay to the patient’s primary care provider about suggested follow-up care after the patient is discharged from the hospital.

    “Hospitalists don’t necessarily type up their day-to-day progress notes as part of the discharge summary.” As a result, both physician- and LLM-generated summaries contained these types of omissions, explained Liu, who recently led AI workshops at national conferences for hospital medicine and internal medicine.

    The discharge summaries also may not have included consultation notes, vital signs, lab values, radiology, pathology, and other clinical reports, she said.

    In terms of causing harm, what was omitted might have improved the quality of the patient’s care, but it wouldn’t have severely impacted it, Liu said. One discharge summary omitted that the patient should have taken certain antibiotics. “Obviously it would be better to have been included. It was not so critical to cause harm, based on the study.” 

    Farzana Hoque, MD, an academic hospitalist in Missouri, was more alarmed by the errors.

    “In this study, omissions were twice as common in LLM-generated summaries compared to human ones — a significant patient safety concern,” she said. For instance, failing to document that a patient’s doctor should follow up on a lung cancer concern could delay diagnosis and treatment, said Hoque, associate professor of medicine at Saint Louis University, St. Louis.

    “Beyond patient safety, such omissions may also elevate malpractice risk for clinicians.” 

    photo of Farzana Hoque
    Farzana Hoque, MD

    Rosner said that if doctors make errors similar to LLM, it represents an opportunity for the latter to create the discharge summaries and reduce the documentation burden on physicians and ultimately curb burnout.

    “We know LLMs are improving at summarizing.” So there’s a potential for LLMs to move into clinical use and summarize clinical encounters, he said. Clinicians still need to review the LLM-generated summaries, ensure they are accurate and of high quality, and edit them before signing off on them.

    Future for Automated Summaries 

    Armed with the results of the UCSF study, next steps are for health systems to test a functional LLM tool to create discharge summaries in clinical settings, Rosner said. The process could be similar to how clinicians review AI medical scribe transcription technology, which already is being widely adopted, he said.

    Large commercial electronic health record vendors are expected to soon release hospital summarization tools like what was studied at UCSF. “We will be assessing it ourselves,” Rosner said.

    “It’s time now to study the implementation of those kinds of tools in actual clinical care. We need to prove the quality of the summaries from LLM before we roll it out to scale,” he said. Rosner added that UCSF also plans to pilot its own LLM discharge summary tool.

    Raghu Subramanian said researchers will need to test the safety, accuracy, and feasibility of any AI tool developed to create discharge summaries.

    “In practice, when I use a tool, I decide how effective, safe, and easy to use it is.” Any LLM discharge summary tool “still needs a very astute, attentive human in the loop. It still needs to be reviewed by clinicians.”

    Roni Robbins is a freelance journalist and former editor for Medscape Business of Medicine. She’s also a freelance health reporter for The Atlanta Journal-Constitution. Her writing has appeared in WebMD, HuffPost, Forbes, New York Daily News, BioPharma Dive, MNN, Adweek, Healthline, and others. She’s also the author of the multi-award–winning novel Hands of Gold: One Man’s Quest to Find the Silver Lining in Misfortune.

    Continue Reading

  • Malaysia's end-July palm oil stocks to hit near two-year high – Reuters

    1. Malaysia’s end-July palm oil stocks to hit near two-year high  Reuters
    2. Palm Oil Stockpiles in Malaysia Seen Surging to 19-Month High  Bloomberg.com
    3. CPO Futures Set To Trade With Downward Bias Next Week  bernama
    4. Palm oil opens lower on weak Dalian rivals, crude oil  NST Online
    5. Palm reverses course to rise but set for second weekly loss  Business Recorder

    Continue Reading

  • bp announces hydrocarbon discovery at Bumerangue exploration well, offshore Brazil | News and insights

    bp announces hydrocarbon discovery at Bumerangue exploration well, offshore Brazil | News and insights

    bp drilled exploration well 1-BP-13-SPS at the Bumerangue block, located in the Santos Basin, 404 kilometres (218 nautical miles) from Rio de Janeiro, in a water depth of 2,372 metres. The well was drilled to a total depth of 5,855 metres.

     

    The well intersected the reservoir about 500 metres below the crest of the structure and penetrated an estimated 500 metre gross hydrocarbon column in high-quality pre-salt carbonate reservoir with an areal extent of greater than 300 square kilometres. 

     

    Results from the rig-site analysis indicate elevated levels of carbon dioxide. bp will now begin laboratory analysis to further characterize the reservoir and fluids discovered, which will provide additional insight into the potential of the Bumerangue block. Further appraisal activities are planned to be undertaken, subject to regulatory approval.

     

    “We are excited to announce this significant discovery at Bumerangue, bp’s largest in 25 years”

     

    Gordon Birrell, EVP, production & operations 

     

    bp holds 100% participation in the block with Pré-Sal Petróleo S.A. as the Production Sharing Contract manager. bp secured the block in December 2022 during the 1st Cycle of the Open Acreage of Production Sharing of ANP, on very good commercial terms.

     

    Gordon Birrell, bp’s executive vice president for Production & Operations said: “We are excited to announce this significant discovery at Bumerangue, bp’s largest in 25 years. This is another success in what has been an exceptional year so far for our exploration team, underscoring our commitment to growing our upstream. Brazil is an important country for bp, and our ambition is to explore the potential of establishing a material and advantaged production hub in the country.” 

     

    Bumerangue is bp’s tenth discovery in 2025 to date. bp has already announced oil and gas exploration discoveries at: Beryl and Frangipani in Trinidad, Fayoum 5 and El King in Egypt, Far South in the Gulf of America, Hasheem in Libya and Alto de Cabo Frio Central in Brazil, plus discoveries in Namibia and Angola through Azule Energy, its 50-50 joint venture with Eni. 

     

    bp plans to grow its global upstream production to 2.3-2.5 million barrels of oil equivalent a day in 2030, with the capacity to increase production out to 2035. 

     

    This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of BP p.l.c., is Ben Mathews, Company Secretary.

    Continue Reading

  • JERA and bp launch offshore wind joint venture JERA Nex bp | News and insights

    JERA and bp launch offshore wind joint venture JERA Nex bp | News and insights

    LONDON AND TOKYO: JERA and bp have completed the formation of JERA Nex bp, their new 50:50-owned joint venture (JV).

    JERA Nex bp is a global offshore wind developer, owner and operator. The new company’s portfolio of operating assets and development projects has a net potential generating capacity of 13GW. This includes around 1GW of installed net generating capacity, a 7.5GW development pipeline and an additional 4.5GW of secured leases.

    JERA Nex bp will initially focus on disciplined and prioritized development of projects from its existing global pipeline while continuing to safely and efficiently operate existing assets in Europe and Asia. It will also seek to continuously prioritize and optimize its portfolio of projects based on value and will leverage access to external capital and competitive financing.

    Nathalie Oosterlinck, CEO of JERA Nex bp, said: “JERA Nex bp begins life with a strong operating portfolio and an extensive development pipeline. We bring together two highly capable teams with the experience, relationships, purchasing power and unique global access of two of the East and West’s pre-eminent energy companies. This gives us the expertise and experience to find new ways to create value from offshore wind and become one of the world’s leading companies in the sector.”

     

     “JERA Nex bp begins life with a strong operating portfolio and an extensive development pipeline. We bring together two highly capable teams with the experience, relationships, purchasing power and unique global access of two of the East and West’s pre-eminent energy companies.”

     

    Nathalie Oosterlinck, CEO, JERA Nex bp

     

    William Lin, bp EVP gas & low carbon energy, added: “Today’s launch marks an important delivery milestone for JERA Nex bp and we are proud to be a partner in this top-tier global offshore wind developer. The JV allows bp to optimize and decapitalize our low carbon energy portfolio as we continue to maintain optionality for electron flows and more material value realization through this decade and the next.

    “JERA is a phenomenal partner with an impressive operating and development portfolio, wealth of expertise and complementary capabilities. With a disciplined, value-driven focus for development, JERA Nex bp will be an incredible vehicle to progress a global pipeline of projects.”

    Satoshi Yajima, chief renewable energy officer of JERA and CEO of JERA Nex, said: “This is a landmark day for JERA’s renewable energy journey. Our partnership with bp has accelerated the growth trajectory of JERA’s overall renewable energy strategy, and the completion of the JV formation reflects the strength and agility that will position JERA Nex bp for long-term success. With support from both partners, JERA Nex bp will serve as a cornerstone in helping the world realize a decarbonized energy future.”

     

    With the transaction completed on August 1, JERA Nex bp Japan – dedicated to developing and operating projects in Japan – has also been established, with Masato Yamada, former Managing Executive Officer of JERA, appointed as CEO. He will report to the CEO of JERA Nex bp.

     

    “This is a landmark day for JERA’s renewable energy journey. Our partnership with bp has accelerated the growth trajectory of JERA’s overall renewable energy strategy, and the completion of the JV formation reflects the strength and agility that will position JERA Nex bp for long-term success.”

     

    Satoshi Yajima, chief renewable energy officer of JERA and CEO of JERA Nex

     

    bp and JERA share a long-standing partnership. JERA Nex bp brings together both companies’ complementary strengths – uniting JERA’s expertise in delivering and safely operating projects with bp’s experience in offshore energy.

    The JV will leverage the pair’s deep engineering, technical and project management expertise, as well as established procurement capabilities and relationships.

    JERA Nex bp has selected its new headquarters in London and is led by a highly experienced management team drawn from both partners, bringing insights into both global access and local markets.

    Mr Takehiko Matsuo, Japan’s Vice-Minister for International Affairs, Ministry of Economy, Trade and Industry, said: “The collaboration between Japanese and UK companies, both with outstanding expertise, experience, and capabilities, is especially meaningful. As one of the world’s leading offshore wind energy companies, a key role in promoting offshore wind on the global stage is strongly expected.”

    Sharon Hodgson MP, UK Trade Envoy to Japan, added: “It’s great that bp and JERA Nex have completed their UK-headquartered joint venture, making them one of the world’s largest offshore wind developers and operators. This marks another strong example of UK-Japan collaboration, highlighting its growing role in advancing clean energy solutions.”

    Continue Reading

  • What’s next for AUD/USD as inflation falls and Fed signals emerge?

    What’s next for AUD/USD as inflation falls and Fed signals emerge?

    Q2 inflation data steers AUD/USD

    AUD/USD finished lower last week at 0.6468, declining 1.48%, marking its largest weekly fall since late March.

    Its decline accelerated after Wednesday’s Australian second-quarter (Q2) consumer price index (CPI) report came in cooler than expected. The Reserve Bank of Australia’s (RBA) preferred inflation measure, the trimmed mean, rose by 0.6% quarter-on-quarter (QoQ), allowing the annual rate to fall to 2.7% from 2.9%.

    This brought inflation closer to the midpoint of the RBA’s 2–3% target range and followed a weak jobs report for June and tepid first-quarter (Q1) growth data – a trifecta widely expected to lead the RBA to cut interest rates by 25 basis points (bp) to 3.60% next week.

    Market reactions to the Fed’s recent announcements

    The downward move in AUD/USD gained further traction on Thursday following a hawkish Federal Open Market Committee (FOMC), which drove it to a low of 0.6418, before rebounding on Friday after the disappointing United States (US) jobs report. The report pushed the markets to price in a 95% probability of a Federal Reserve (Fed) rate cut in September, up from 50% the prior day.

    Focus on upcoming meetings

    Looking ahead, this week’s data calendar is relatively light in both Australia and the US, with little to guide the market away from the prevailing expectation that the RBA will cut rates by 25 bp at its 12 August meeting, and that the Fed will do the same at its September meeting.

    In the absence of new catalysts, we expect AUD/USD to be primarily influenced by factors that are mostly US dollar-negative:  

    • Digesting the weak jobs report
    • Weighing the impact of the latest round of tariffs
    • Ongoing uncertainty created by President Trump’s dismissal of the Bureau of Labor Statistics (BLS) head and his continued attacks on Fed Chair Jerome Powell.

    Continue Reading

  • Japan's Ishiba signals talks with Trump for early cut to US auto tariff – Reuters

    1. Japan’s Ishiba signals talks with Trump for early cut to US auto tariff  Reuters
    2. 15 Pct U.S. Tariff to Be Imposed on Japanese Goods from Aug. 7  nippon.com
    3. Akazawa, said trade agreement between the US & Japan is not a legally binding commitment  investingLive
    4. ‘So Trump-like’: relief but no surprise in Japan as US cuts tariffs  El Paso Inc.
    5. ARTHUR CYR: The trade deal with Japan – more than meets the eye  nwitimes.com

    Continue Reading

  • Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

    HONG KONG, Aug. 4, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). The trial will evaluate cadonilimab, Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with atezolizumab (a PD-L1 inhibitor) and bevacizumab. Akeso is now moving forward with the initiation of the study.

    The COMPASSION-36/AK104-225 study is a key part of cadonilimab’s global development for hepatocellular carcinoma, continuing Akeso’s mission to advance cancer immunotherapy standards and to address the current limited survival benefits of single-target therapies.  This international, multicenter Phase II trial is designed to tackle the common issue of limited treatment options following resistance to immune checkpoint inhibitors (IO) in cancer therapy.

    Currently, immune checkpoint inhibitor (IO) combination therapies have become the standard first-line treatment for various advanced malignancies. However, for patients worldwide whose disease progresses after IO combination therapy, there is a lack of effective second-line treatment options. The very limited second-line treatment options for advanced malignancies drives the critical need to explore new therapeutic strategies. Cadonilimab-based combination therapies have shown substantial potential in overcoming IO resistance across multiple tumor types.

    Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, with approximately 865,000 new cases of liver cancer reported globally in 2022. The combination of atezolizumab and bevacizumab (A+T regimen) is the standard first-line therapy for advanced HCC, as recommended by the NCCN guidelines. However, for patients whose disease progresses after first-line A+T treatment, there is currently no FDA-approved second-line therapy available in the U.S., and also no approved treatment options from the NMPA in China. This creates a significant unmet need in the clinical management of these patients.

    Cadonilimab is the first bispecific antibody for cancer immunotherapy to be approved globally and also the first bispecific antibody to be approved in China. The potential of cadonilimab for the treatment of HCC has been validated in multiple studies:

    • At the 2023 European Society for Medical Oncology Asia Congress (ESMO Asia), a study was presented demonstrating that cadonilimab, combined with FOLFOX-HAIC as neoadjuvant therapy, achieved a 100% disease control rate (DCR) in patients with resectable multinodular HCC, with an acceptable safety profile.
    • Additionally, data presented at the 2023 European Society for Medical Oncology (ESMO) Congress revealed that the combination of cadonilimab and lenvatinib as first-line treatment for advanced HCC shows superior antitumor activity compared to currently approved therapies for advanced HCC.

    Akeso’s exploration of combination therapies with cadonilimab in the treatment of HCC offers a broad and effective approach to disease management. These combinations address both early and advanced stages of HCC and provide promising therapeutic options for a wide range of patients:

    • In addition to the international multicenter Phase II registrational study COMPASSION-36, patient enrollment for the Phase III clinical trial of cadonilimab as adjuvant therapy for high-risk recurrence following curative surgery for HCC has been completed.
    • Furthermore, a Phase III registrational study of cadonilimab combined with lenvatinib and transarterial chemoembolization (TACE) for the treatment of intermediate to advanced unresectable HCC is currently ongoing.
    • Additionally, multiple Phase II studies investigating cadonilimab in combination with pulocimab (VEGFR-2), ivonescimab (PD-1/VEGF), and other therapies are currently underway for PD-1/L1 inhibitor-resistant non-small cell lung cancer (NSCLC), HCC, and other malignancies. These studies demonstrate cadonilimab’s potential in treating IO-resistant tumors.

    Dr. Yu Xia, Founder, Chairwoman, President, and CEO of Akeso, remarked, “We are excited to initiate cadonilimab’s first international multicenter registrational trial, a pivotal step in addressing the global challenge of cancer immunotherapy resistance. This study represents a key milestone in Akeso’s global strategy to address the substantial clinical unmet needs in oncology. Akeso is advancing the clinical development of its innovative pipeline, including ivonescimab, cadonilimab, ligufalimab (CD47), and AK146D1 (Trop2/Nectin4 bispecific ADC) through both in-house initiatives and strategic global collaborations. Our goal is to provide accessible and impactful survival benefits to patients worldwide, and to position Akeso at the forefront of oncology innovation.”

    Forward-Looking Statement of Akeso, Inc.

    This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

    Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

    About Akeso

    Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

    For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

    SOURCE Akeso, Inc.

    Continue Reading

  • Food Insecurity Linked to Rapid Mental Health Deterioration

    Food Insecurity Linked to Rapid Mental Health Deterioration

    TOPLINE:

    Food insecurity predicted and was associated with increased symptoms of anxiety and depression within 1 month, new research showed. However, mental health improved rapidly when food security was restored.

    METHODOLOGY:

    • Researchers conducted a secondary analysis of Changing Cost of Living Study data for 240 adults from France and 244 adults from the UK between 2022 and 2023.
    • Food insecurity was measured using three items from the United Nations Global Food Insecurity Experience Scale with a 1-week reference period, yielding scores from 0 (food secure) to 3 (severe food insecurity).
    • Anxiety and depression were measured using the seven-item Generalized Anxiety Disorder questionnaire (GAD-7) and eight-item Patient Health Questionnaire (PHQ-8) scores, respectively, with reference periods of 2 weeks.
    • Additionally, analyses were conducted “within individuals” (how a single individual’s characteristics change) and “between individuals” (how individuals differ from each other).

    TAKEAWAY:

    • Within-individual analysis showed that food-insecure vs food-secure months were associated with increased concurrent symptoms of anxiety (mean standardized GAD-7 score, 0.15; P < .001) and depression (mean standardized PHQ-8 score, 0.11; P = .005).
    • Between-individual analysis showed an even stronger association between food insecurity and poor mental health, with nearly fivefold higher mean standardized scores on the GAD-7 (0.71) and sevenfold higher scores on the PHQ-8 (0.76; P < .001 for both) than those in the within-individual analysis.
    • The associations between food insecurity and poor mental health persisted even after controlling for sex, age, time, and mental health in the previous month.
    • Additional data showed that eliminating food insecurity could potentially reduce clinically relevant anxiety and depression symptoms by 20.79 and 19.47 percentage points, respectively, in affected populations.

    IN PRACTICE:

    “The effects were rapid, occurring within a month of becoming food insecure, and were equally rapidly reversed,” the investigators wrote.

    “Consistent with Granger causality, food insecurity in the current month predicted poorer mental health in the following month after controlling for current mental health,” which supports the hypothesis that food insecurity may cause anxiety and depression symptoms, they added.

    SOURCE:

    The study was led by Melissa Bateson, Biosciences Institute, Newcastle University, Newcastle upon Tyne, England. It was published online on July 16 in PLOS Mental Health.

    LIMITATIONS:

    The study panels were not nationally representative, and all measurements relied on self-reported data, potentially introducing a reporting bias. Additionally, the intensive longitudinal design of the study did not permit causal inferences comparable to those from experimental studies.

    DISCLOSURES:

    The study was funded by Agence Nationale de la Recherche, UK Prevention Research Partnership, National Institute for Health and Care Research, and University of York Cost of Living Research Group. The investigators reported having no relevant conflicts of interest.

    This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

    Continue Reading

  • Dollar finds footing after US jobs drubbing – Reuters

    1. Dollar finds footing after US jobs drubbing  Reuters
    2. US jobs jolt fans Fed rate cut buzz; Indian rupee to ride dollar slump  Business Recorder
    3. The weekender: Jobs report to Powell, ‘hold my beer’  FXStreet
    4. Euro to Dollar forecast: EUR/USD climbs back to 1.1550  Latest news from Azerbaijan
    5. Singapore Dollar Strengthens Amid U.S. Slowdown Worries  The Wall Street Journal

    Continue Reading

  • Rupee falls 11 paise to 87.29 against U.S. dollar in early trade

    Rupee falls 11 paise to 87.29 against U.S. dollar in early trade

     On Friday, the rupee closed at 87.18 against the U.S. dollar. File.
    | Photo Credit: Reuters

    The rupee depreciated 11 paise to 87.29 against the U.S. dollar in early trade on Monday (August 4, 2025), weighed down by sustained foreign fund outflows and concerns over trade tariffs.

    Forex traders said the weakness in the dollar index and easing crude oil prices supported the rupee at lower levels.

    At the interbank foreign exchange market, the rupee opened at 87.21 and fell to an early low of 87.29 against the American currency, registering a decline of 11 paise over its previous close.

    On Friday, the rupee closed at 87.18 against the U.S. dollar.

    “Indian Rupee opened at 87.20 level this morning after the fall in Dollar index and is expected to be in the range of 87- 87.50,” said Anil Kumar Bhansali, Head of Treasury and Executive Director, Finrex Treasury Advisors LLP.

    Mr. Trump also outlined steep duties against 70 countries, raising uncertainty over trade tariffs, Bhansali said.

    Meanwhile, Brent crude prices fell 0.26% to $69.49 per barrel in futures trade, as OPEC+ agreed for a production hike in September this year, while concerns over a cooling US economy and trade tariffs also weighed.

    The dollar index, which gauges the greenback’s strength against a basket of six currencies, fell by 0.40% to 98.74.

    Meanwhile, the U.S. FED Governor resigned, opening the door for U.S. President Donald Trump to make an imprint on the Central Bank much earlier than anticipated.

    The U.S. Treasury yields also fell as traders heavily scaled up bets of a FED rate cut in September.

    In the domestic equity market, Sensex advanced 262.08 points or 0.33% to 80,861.99, while Nifty rose 98.50 points or 0.4% to 24,663.85.

    Foreign institutional investors (FIIs) offloaded equities worth ₹3,366.40 crore on a net basis on Friday, according to exchange data.

    Continue Reading